Categories: News

Amicus Therapeutics to Announce Second Quarter 2022 Financial Results on August 4, 2022

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

PHILADELPHIA, July 26, 2022 (GLOBE NEWSWIRE) — Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, August 4, 2022 at 8:30 a.m. ET to discuss financial results for the second quarter ended June 30, 2022.

Interested participants and investors may access the conference call by dialing 1-833-634-2601 (U.S. Toll Free) or 1-412-902-4113 (International). A live audio webcast and related presentation materials can also be accessed via the Investors section of the Amicus Therapeutics corporate website at ir.amicusrx.com. Web participants are encouraged to register on the website 15 minutes prior to the start of the call.

A replay of the call will be available for seven days beginning two hours after the conclusion of the event. Access numbers for this replay are 1-877-344-7529 (U.S. Toll Free), 1-855-669-9658 (Canada Toll Free), and 1-412-317-0088 (International); Access Code: 3033146.

About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. For more information please visit the company’s website at www.amicusrx.com, and follow on Twitter and LinkedIn.

CONTACT:

Investors:
Amicus Therapeutics
Andrew Faughnan
Executive Director, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809

Media:
Amicus Therapeutics
Diana Moore
Head of Global Corporate Communications
dmoore@amicusrx.com
(609) 662-5079

FOLD–G

Staff

Recent Posts

The Pause Technologies Completes Participation in 2025 Mayo Clinic and ASU MedTech Accelerator

SCOTTSDALE, Ariz., April 2, 2025 /PRNewswire/ -- The Pause Technologies, a real-time AI platform dedicated…

3 hours ago

HiTouch, a Mobile App that Improves the Happiness of Individuals and Organizations

SEOUL, South Korea, April 3, 2025 /PRNewswire/ -- As the social atmosphere emphasizes the importance of…

3 hours ago

PreveCeutical Announces Update to Non-Brokered Private Placement

Vancouver, British Columbia--(Newsfile Corp. - April 2, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB:…

7 hours ago

Lam Research Corporation Announces March Quarter Financial Conference Call

FREMONT, Calif., April 2, 2025 /PRNewswire/ -- Lam Research Corp. (NASDAQ: LRCX) today announced that…

9 hours ago

Former Pfizer R&D Chief Mikael Dolsten Joins Formation Bio to Chair Drug Picking Committee and Co-Chair its Investment Advisory Committee

NEW YORK, April 2, 2025 /PRNewswire/ -- Formation Bio, an AI-driven pharmaceutical company revolutionizing drug development,…

9 hours ago

Siemens acquires Dotmatics to extend AI-powered software portfolio to Life Sciences

Acquisition of Dotmatics, a leader in Life Sciences R&D software for $5.1 billionExpands Siemens' market-leading…

9 hours ago